Abstract
Basal telomerase activity is dependent on expression of the hTERT and hTR genes and upregulation of telomerase gene expression is associated with tumour development. It is therefore possible that signal transduction pathways involved in tumour development and features of the tumour environment itself may influence telomerase gene regulation. The majority of solid tumours contain regions of hypoxia and it has recently been demonstrated that hypoxia can increase telomerase activity by mechanisms that are still poorly defined. Here, we show that hypoxia induces the transcriptional activity of both hTR and hTERT gene promoters. While endogenous hTR expression is regulated at the transcriptional level, hTERT is subject to regulation by alternative splicing under hypoxic conditions, which involves a switch in the splice pattern in favour of the active variant. Furthermore, analysis of the chromatin landscape of the telomerase promoters reveals dynamic recruitment of a transcriptional complex involving the hypoxia-inducible factor-1 transcription factor, p300, RNA polymerase II and TFIIB, to both promoters during hypoxia, which traffics along and remains associated with the hTERT gene as transcription proceeds. These studies show that hTERT and hTR are subject to similar controls under hypoxia and highlight the rapid and dynamic regulation of the telomerase genes in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA et al. (1996). Proc Natl Acad Sci USA 93: 12969–12973.
Ashcroft M, Bardos JI . (2004). Bioessays 26: 262–269.
Atkinson SP, Hoare SF, Glasspool RM, Keith WN . (2005). Canc Res (in press).
Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TRJ, Ganly I et al. (2003). Oncogene 22: 370–380.
Blasco MA, Hahn WC . (2003). Trends Cell Biol 13: 289–294.
Chen H, Hahn S . (2004). Cell 119: 169–180.
Elsby LM, Roberts SGE . (2004). Biochem Soc Trans 32: 1098–1099.
Forsythe JA, Jiang B, Iyer NV, Agani F, Leung SW, Koos RD et al. (1996). Mol Cell Biol 16: 4604–4613.
Freedman SJ, Sun ZJ, Poy F, Kung AL, Livingston DM, Wagner G et al. (2002). Proc Natl Acad Sci USA 99: 5367–5372.
Gomez-Roman N, Grandori C, Eisenman RN, White RJ . (2003). Nature 421: 290–294.
Gorbunova V, Seluanov A, Pereira-Smith OM . (2002). J Biol Chem 277: 38540–38549.
Graven KK, Troxler RF, Kornfeld H, Panchenko MV, Farber HW . (1994). J Biol Chem 269: 24446–24453.
Hahn S . (2004). Nat Struct Mol Biol 11: 394–403.
Hashimoto Y, Zhang C, Kawauchi J, Imoto I, Adachi MT, Inazawa J et al. (2002). Nucleic Acid Res 30: 2398–2406.
Hockel M, Vaupel P . (2001). J Natl Cancer Inst 93: 266–276.
Kallio PJ, Okamoto K, O’Brien S, Carrero P, Makino Y, Tanaka H et al. (1998). EMBO J 17: 6573–6586.
Kilian A, Bowtell DDL, Abud HE, Hime GR, Venter DJ, Keese PK et al. (1997). Hum Mol Genet 6: 2011–2019.
Kornblihtt AR, De La Mata M, Fededa JP, Munoz MJ, Nogues G . (2004). RNA 10: 1489–1498.
Kung AL, Wang S, Klco JM, Kaelin Jr WG, Livingston DM . (2000). Nat Med 6: 1335–1340.
Luiten RM, Pene J, Yssel H, Spits H . (2003). Blood 101: 4512–4519.
Minamino T, Mitsialis SA, Kourembanas S . (2001). Mol Cell Biol 21: 3336–3342.
Misteli TaSDL . (1999). Mol Cell 3: 697–705.
Munch C, Zhu B, Leven A, Stamm S, Einkorn H, Schwalenstocker B et al. (2003). J Neurosci Res 71: 819–825.
Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K . (2004). Mol Cell Biol 24: 6076–6083.
Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ et al. (2001). Oncogene 20: 7797–7803.
Reynolds TY, Rockwell S, Glazer PM . (1996). Cancer Res 56: 5754–5757.
Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee A, Yoshida H et al. (2004). Cancer Res 64: 5943–5947.
Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuro T . (1999). Biochem Biophys Res Commun 260: 365–370.
Shi Y, Sawada J, Sui G, Affar EB, Whetstine JR, Lan F et al. (2003). Nature 422: 735–738.
Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR . (1998). Cancer Res 58: 4168–4172.
Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, Kanaya T et al. (2004). Oncogene 23: 3708–3715.
Zaffaroni N, Porta CD, Villa R, Botti C, Buglioni S, Mottolese M et al. (2002). J Pathol 198: 37–46.
Zhang C, Dowd DR, Staal A, Gu C, Lian JB, van Wijnen AJ et al. (2003a). J Biol Chem 278: 35325–35336.
Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M et al. (2003b). Cancer Res 63: 4552–4560.
Acknowledgements
Research is supported by Cancer Research UK, Glasgow University and European Community Grant LSHC-CT-2004–502943.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anderson, C., Hoare, S., Ashcroft, M. et al. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25, 61–69 (2006). https://doi.org/10.1038/sj.onc.1209011
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209011
Keywords
This article is cited by
-
Diverse regulatory manners of human telomerase reverse transcriptase
Cell Communication and Signaling (2019)
-
Reactivation of telomerase in cancer
Cellular and Molecular Life Sciences (2016)
-
Severe hypoxia exerts parallel and cell-specific regulation of gene expression and alternative splicing in human mesenchymal stem cells
BMC Genomics (2014)
-
The growing complexity of HIF-1α’s role in tumorigenesis: DNA repair and beyond
Oncogene (2013)
-
Non-protein coding RNA biomarkers and differential expression in cancers: a review
Journal of Experimental & Clinical Cancer Research (2008)